Literature DB >> 30341980

Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records.

Krista F Huybrechts1, Chandrasekar Gopalakrishnan1, Jessica M Franklin1, Kristina Zint2, Lionel Riou Franca2, Dorothee B Bartels3,4, Joan Landon1, Sebastian Schneeweiss1.   

Abstract

Claims databases provide information on the effects of direct oral anticoagulants (DOACs) as used in routine care but may not contain important data on clinical characteristics, which may be captured in electronic health records (EHRs). Within a US claims database, we identified patients initiating a DOAC or warfarin between October 2010 and December 2014. Propensity score (PS) matching, 1:1, was used to balance 78 claims-defined baseline characteristics. We evaluated whether balance was achieved in patient characteristics immeasurable in the claims data study by evaluating the balance in clinical information (using absolute standardized differences (aSDs)) from linked EHR data. From a claims data cohort study of 140,187 patients, 5,935 (4.2%) were linked to EHR data. After PS matching, almost all EHR-defined patient characteristics were well balanced (aSD < 0.1). A new user active comparator design with 1:1 PS matching on many patient characteristics improved balance on clinical risk factors observed in EHRs but not in claims data.
© 2018 The Authors Clinical Pharmacology & Therapeutics © 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30341980      PMCID: PMC6422763          DOI: 10.1002/cpt.1256

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease.

Authors:  Andrew D Rule; Timothy S Larson; Erik J Bergstralh; Jeff M Slezak; Steven J Jacobsen; Fernando G Cosio
Journal:  Ann Intern Med       Date:  2004-12-21       Impact factor: 25.391

3.  Methods for comparative effectiveness research/patient-centered outcomes research: from efficacy to effectiveness.

Authors:  Sebastian Schneeweiss; John D Seeger; John W Jackson; Scott R Smith
Journal:  J Clin Epidemiol       Date:  2013-08       Impact factor: 6.437

4.  Improving therapeutic effectiveness and safety through big healthcare data.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2016-01-17       Impact factor: 6.875

5.  When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?

Authors:  Jessica M Franklin; Sebastian Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2017-09-25       Impact factor: 6.875

6.  Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Circulation       Date:  2014-10-30       Impact factor: 29.690

7.  Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Ya-Hui Hsueh; Rima Izem; Mary Ross Southworth; Yuqin Wei; Jiemin Liao; Margie R Goulding; Katrina Mott; Yoganand Chillarige; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  JAMA Intern Med       Date:  2016-11-01       Impact factor: 21.873

8.  Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study.

Authors:  B M Psaty; L H Kuller; D Bild; G L Burke; S J Kittner; M Mittelmark; T R Price; P M Rautaharju; J Robbins
Journal:  Ann Epidemiol       Date:  1995-07       Impact factor: 3.797

9.  Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores.

Authors:  P Mona Eng; John D Seeger; Jeanne Loughlin; C Robin Clifford; Sherry Mentor; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-03       Impact factor: 2.890

10.  Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.

Authors:  John D Seeger; Katsiaryna Bykov; Dorothee B Bartels; Krista Huybrechts; Kristina Zint; Sebastian Schneeweiss
Journal:  Thromb Haemost       Date:  2015-10-08       Impact factor: 5.249

View more
  2 in total

1.  Use of Linked Databases for Improved Confounding Control: Considerations for Potential Selection Bias.

Authors:  Jenny W Sun; Rui Wang; Dongdong Li; Sengwee Toh
Journal:  Am J Epidemiol       Date:  2022-03-24       Impact factor: 5.363

2.  Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

Authors:  Wayne A Ray; Cecilia P Chung; C Michael Stein; Walter Smalley; Eli Zimmerman; William D Dupont; Adriana M Hung; James R Daugherty; Alyson Dickson; Katherine T Murray
Journal:  JAMA       Date:  2021-12-21       Impact factor: 157.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.